Format

Send to

Choose Destination
J Pediatr Hematol Oncol. 2019 May 29. doi: 10.1097/MPH.0000000000001521. [Epub ahead of print]

Emergence of a Ph-negative Clone in a Child With Ph+ ALL.

Author information

1
Department of Pediatrics.
2
Division of Pediatric Hematology/Oncology, Health Sciences Division, Loyola University Chicago, Maywood, IL.

Abstract

The addition of tyrosine kinase inhibitors to conventional chemotherapy has improved outcomes for pediatric patients with Philadelphia chromosome-positive (Ph) acute lymphoblastic leukemia (ALL). However, the rate of relapse is still higher compared with many other types of pediatric ALL, with many possible mechanisms for resistance. We describe an 8-year-old boy with Ph ALL relapsing with ALL without the Ph following treatment with dasatinib as a part of Children's Oncology Group trial AALL1122. This emphasizes the polyclonal nature of ALL at diagnosis and indicates that the BCR-ABL fusion oncogene is not always an essential "driver" mutation.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center